Cargando…
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
Support for the N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia has led to increasing focus on restoring proper glutamatergic signaling as an approach for treatment of this devastating disease. The ability of metabotropic glutamate (mGlu) receptors to modulate glutamat...
Autores principales: | Maksymetz, James, Moran, Sean P., Conn, P. Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405554/ https://www.ncbi.nlm.nih.gov/pubmed/28446243 http://dx.doi.org/10.1186/s13041-017-0293-z |
Ejemplares similares
-
Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease
por: Luessen, Deborah J., et al.
Publicado: (2022) -
Targeting of Metabotropic Glutamate Receptors for the Development of
Novel Antidepressants
por: Chaki, Shigeyuki, et al.
Publicado: (2019) -
The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia
por: Maj, Carlo, et al.
Publicado: (2016) -
43.1 GENETIC INSIGHTS LEAD TO DISCOVERY OF SELECTIVE ACTIVATORS OF MGLU1 AND MGLU3 METABOTROPIC GLUTAMATE RECEPTORS AS POTENTIAL TREATMENTS FOR SCHIZOPHRENIA
por: Conn, P Jeffrey, et al.
Publicado: (2018) -
T227. THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 REGULATES STRIATAL DOPAMINE RELEASE VIA AN ENDOCANNABINOID-DEPENDENT MECHANISM: IMPLICATIONS FOR THE TREATMENT OF SCHIZOPHRENIA
por: Yohn, Samantha, et al.
Publicado: (2018)